Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine.
Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine.
复制标题
经验与理由：奥卡株水痘活疫苗保护性免疫二十年随访。
DOI：
10.1542/peds.94.4.524
复制
发表时间：
1994
期刊：
影响因子：
8
通讯作者：
Shigemitsu Ito
中科院分区：
文献类型：
--
作者：
Y. Asano;S. Suga;T. Yoshikawa;I. Kobayashi;T. Yazaki;Motohiro Shibata;K. Tsuzuki;Shigemitsu Ito
自1974年首次报道水痘减毒活疫苗以来，该疫苗在健康儿童和白血病儿童中得到了广泛的研究，并取得了良好的结果。它现在在日本，韩国和一些欧洲国家获得许可，并正在考虑在美国获得许可。虽然各种临床试验已经确定了疫苗的安全性，免疫原性和有效性，但人们担心疫苗接种者的免疫力下降可能会导致日后发生更严重的水痘。我们在对疫苗接种者进行的大约20年的随访研究中显示了与这一问题相关的数据;这项工作进一步扩展了疫苗长期保护效力的经验。
Since the first report on the development of a live attenuated varicella vaccine in 1974, the vaccine has been studied extensively, with largely favorable results, in both healthy and leukemic children. It is now licensed in Japan, Korea, and some European countries, and is being considered for licensure in the United States. Although various clinical trials have established the safety, immunogenicity, and the efficacy of the vaccine, concern has been expressed that waning immunity in the vaccine recipients might allow the occurrence of more severe varicella later in life. We show data relevant to this concern on the approximately 20-year follow-up study of the vaccine recipients; this work further extends the experience of a long-term protective efficacy of the vaccine.